Skip to main content
TipRanks
Go Ultimate75% OFF

Viatris (1VTRS) Q3 2026 Earnings Report

1 Followers

IT:1VTRS Q3 2026 EPS Results

Actual EPS
EUR 0.65
Consensus EPS
EUR 0.58
Beat/Miss
Beat by +EUR 0.07
One Year Ago EPS
EUR 0.61

IT:1VTRS Q3 2026 Revenue Results

Actual Revenue
EUR 3.41B
Expected Revenue
EUR 3.44B
Beat/Miss
Missed by -EUR 31.22M
YoY Revenue Growth
-0.28%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
Before Open
Conference Call
Thursday, November 5, 2026
IT:1VTRS Upcoming Earnings

Viatris's next earnings date is estimated for March 1, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

IT:1VTRS Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:6.18%|
Earnings Call Sentiment|Positive

The call was strongly positive overall. Viatris reported solid Q3 and nine-month financial growth, raised 2026 guidance, highlighted accelerating North American growth, continued Greater China momentum, strong cash flow, substantial pipeline progress, and expected benefits from the proposed Pacira acquisition. These positives outweighed challenges from Nashik-related supply constraints, policy-driven China moderation, regional declines, competition, and upcoming loss-of-exclusivity impacts.

Company Guidance

For 2026, excluding contributions from the proposed acquisition of Pacira, Viatris expects at the midpoint of its revised guidance ranges operational growth of approximately 2% for total revenues, 6% for adjusted EBITDA and 8% for adjusted EPS versus the prior year; by region, North America is expected to be in the high single-digit range, Europe flattish, emerging markets and JANZ low single-digit declines, and Greater China closer to the low double-digit range, while fourth-quarter supply disruptions are expected to impact total revenues by approximately $100 million, and net savings from the strategic review are expected to reach $120 million this year. Viatris expects the Pacira transaction to close before the end of November, be immediately accretive to all financial guidance metrics in 2027 versus expected 2026 results, generate more than $50 million in annual cost synergies by the end of 2028, and help its U.S. innovative medicines business generate more than $1 billion in total revenue in 2027; Greater China is expected to grow in 2027, albeit closer to historical averages in the low to mid-single-digit range, and the company expects its patches to reach 1.5 million women in 2026 and add in 2027 another 1 million of women using its patches.

  • Strong Third-Quarter and Year-to-Date Financial PerformanceQ3 total revenues were $3.75 billion, adjusted EBITDA was $1.2 billion, and adjusted EPS was $0.71 per share. Through the first nine months, total revenues grew 2%, adjusted EBITDA grew 6%, and adjusted EPS grew 8% operationally versus the prior year.
  • Raised 2026 Financial GuidanceViatris narrowed its 2026 guidance ranges and raised the midpoint for all key financial metrics. At the midpoint, the company expects operational growth of approximately 2% for total revenues, 6% for adjusted EBITDA, and 8% for adjusted EPS versus the prior year.
  • North America Growth and Portfolio Mix ImprovementNorth America net sales grew approximately 7% year over year and exceeded expectations, driven primarily by higher-margin complex generics, including estradiol patch products. Complex injectables, respiratory medicines, and HRT transdermals represented an increasing portion of the U.S. portfolio, with the company expecting North America growth in the high single-digit range for 2026.
  • Strong Estradiol Patch Demand and Capacity ExpansionNorth American estradiol patch volumes were approximately double the prior-year period, and quarterly net sales exceeded expectations. Viatris expanded the plant from 24/5 to 24/7 utilization, is adding a packaging line, and is evaluating geographic expansion outside Vermont. The company expects its patches to reach 1.5 million women in 2026 and add another 1 million women in 2027.
  • Greater China GrowthGreater China net sales grew approximately 10% year over year in Q3, with growth across all channels, including continued e-commerce uptake. Growth was driven by strong demand for established brands and the cardiovascular portfolio, and management expects China to continue growing in 2027, albeit closer to historical low- to mid-single-digit levels.
  • Improved Adjusted Gross Margin and Operating LeverageAdjusted gross margin was 58%, above expectations, driven by growth in Greater China and North America. Operating expenses were in line with expectations and declined slightly as a percentage of revenue versus the prior year, reflecting spending discipline and the enterprise-wide strategic review.
  • Strategic Review Savings ProgressViatris remains on track to achieve $120 million of net savings from its strategic review in 2026.
  • Strong Free Cash Flow and Shareholder ReturnsQ3 free cash flow was $814 million, exceeding expectations, or $895 million excluding transaction and restructuring-related costs and taxes. Through the first three quarters, the company returned approximately $717 million to shareholders, including $300 million of share repurchases and the remainder through quarterly dividends.
  • Manageable Leverage PositionViatris exited the quarter with gross leverage of approximately 2.9x, below the midpoint of its long-term target range of 2.8x to 3.2x.
  • Pacira Acquisition Expected to Expand U.S. Innovative MedicinesViatris expects the proposed Pacira acquisition to add the established patent-protected U.S. medicines EXPAREL and ZILRETTA and strengthen its U.S. Promoted Brands business. With Pacira's products, the company expects its U.S. innovative medicines business to generate more than $1 billion of total revenue in 2027.
  • Pacira Financial Benefits and SynergiesThe transaction is expected to be immediately accretive to all financial guidance metrics in 2027 versus expected 2026 results. Viatris expects to realize more than $50 million in annual cost synergies by the end of 2028, with potential for additional savings as integration progresses. The transaction is expected to have a minimal impact on gross leverage.
  • Pacira Commercial and Strategic CapabilitiesPacira would add U.S. capabilities across sales, marketing, market access, medical affairs, and global R&D. Viatris expects these capabilities to support the launch of fast-acting meloxicam, maximize the long-term value of the Pacira portfolio, and strengthen its position in non-opioid pain management.
  • Progress on Fast-Acting MeloxicamThe FDA review of the fast-acting meloxicam NDA is substantially complete, with labeling negotiations expected to begin in November ahead of the December 27 PDUFA date. If approved, Viatris expects to launch the product early in 2027 and views it as a potential addition to acute pain treatment because of its rapid absorption, clinically meaningful pain relief, and demonstrated reduction in opioid use.
  • Innovative Medicines Regulatory ProgressViatris received U.S. approval for Ryzumvi for presbyopia and regulatory approval for Wakix in Japan, which management expects to be an important launch and contributor to returning Japan to growth. The company also submitted a European type 2 variation for Creon to expand its approved dosing range for non-cystic fibrosis indications, with a decision anticipated in the first half of 2027.
  • Women's Health Pipeline ProgressViatris launched the low-dose contraceptive patch Gwyn Lo in the U.S. in October. Its norelgestromin-only weekly patch has completed Phase III enrollment, with data expected in the first half of 2027.
  • Nefecon Development Remains on TrackIn Japan, the Nefecon program for patients with IgA nephropathy continues to advance following positive Phase III results announced earlier in the year. Viatris remains on track to submit its JNDA by the end of 2026, with a regulatory decision anticipated in the second half of 2027.
  • Late-Stage Innovative Pipeline MilestonesBoth Phase III cenerimod studies, OPUS-1 and OPUS-2, are advancing as planned, with results expected in the first half of 2027. The Phase III LUMIOS study in lupus nephritis is actively enrolling. Selatogrel SOS-AMI Phase III enrollment is tracking well, with data also expected around the first half of 2027. The cenerimod pooled analysis is prespecified in the statistical analysis plan.
  • Generic Pipeline ExecutionViatris is on track to secure approval for more than 100 new products in 2026. The company was the first to secure final FDA approval for once-monthly aripiprazole injection in the U.S. and secured first-to-file status for Wegovy or semaglutide 25-milligram tablets. Viatris also said it has developed multiple future semaglutide and tirzepatide presentations, with a primary focus on the U.S.
  • Japan Growth InitiativesJANZ net sales exceeded expectations despite declining year over year. Management cited early uptake of Effexor for generalized anxiety disorder, continued uptake of Spydia, and the expected Wakix launch as factors supporting a future return to growth in Japan.
  • Capital Allocation Priorities MaintainedViatris plans to continue paying its dividend, repurchasing shares, and pursuing business development over the next three to five years. Management said it expects to have sufficient cash to support dividends, buybacks, and accretive business development through 2030.

IT:1VTRS Earnings History

IT:1VTRS earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 01, 20272026 (Q4)0.55-0.52――
Nov 05, 20262026 (Q3)0.580.650.615.97% (+0.04)
Aug 06, 20262026 (Q2)0.550.630.5611.29% (+0.06)
May 07, 20262026 (Q1)0.460.540.4518.00% (+0.08)
Feb 26, 20262025 (Q4)0.480.520.495.56% (+0.03)
Nov 06, 20252025 (Q3)0.560.610.68-10.67% (-0.07)
Aug 07, 20252025 (Q2)0.510.560.63-10.14% (-0.06)
May 08, 20252025 (Q1)0.450.450.61-25.37% (-0.15)
Feb 27, 20252024 (Q4)0.520.490.56-12.90% (-0.07)
Nov 07, 20242024 (Q3)0.620.680.72-4.94% (-0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed